Catalog No.
DHD17405
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
scFv-kappa-heavy
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Epithelial glycoprotein 314, hEGP314, Major gastrointestinal tumor-associated protein GA733-2, EGP314, TACSTD1, Adenocarcinoma-associated antigen, TROP1, EPCAM, Epithelial glycoprotein, KS 1/4 antigen, Tumor-associated calcium signal transducer 1, M4S1, CD326, Ep-CAM, EGP, Epithelial cell adhesion molecule, M1S2, KSA, Cell surface glycoprotein Trop-1, GA733-2, Epithelial cell surface antigen, MIC18
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16422
Form
Liquid
Storage buffer
30 mM histidine pH 5.8, 10% sucrose, 0.02% Tween 80
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Oportuzumab
Note
For research use only. Not suitable for clinical or therapeutic use.
A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin., PMID:22998907
Commentary on "A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin." Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett MA, MacDonald GC: J Urol 2012;188(5):1712-8 [Epub 2012 Sep 19]., PMID:23796197
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments., PMID:29116596
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update., PMID:29295696
Antibodies to watch in 2018., PMID:29300693
Antibody-Drug Conjugates in Bladder Cancer., PMID:30112436
Current Clinical Trials in Non-muscle Invasive Bladder Cancer., PMID:30357541
Antibodies to watch in 2019., PMID:30516432
Antibodies to watch in 2020., PMID:31847708
Antibody-Drug Conjugates in Urothelial Carcinomas., PMID:32008109
The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer., PMID:33742981
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer., PMID:34057394
From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)., PMID:35158964
Emerging treatment landscape of non-muscle invasive bladder cancer., PMID:35634893
ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential., PMID:36439125
Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives., PMID:37403009
Antibody-drug conjugates for urothelial carcinoma., PMID:37419845
Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer., PMID:39104019
The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer, PMID: 33742981
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer, PMID: 34057394
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments, PMID: 29116596
Current Clinical Trials in Non-muscle Invasive Bladder Cancer, PMID: 30357541
Antibodies to watch in 2018, PMID: 29300693
Commentary on "A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin." Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett MA, MacDonald GC: J Urol 2012;188(5):1712-8 [Epub 2012 Sep 19], PMID: 23796197
Antibody-Drug Conjugates in Bladder Cancer, PMID: 30112436
A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin, PMID: 22998907
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, PMID: 29295696
Antibody-Drug Conjugates in Urothelial Carcinomas, PMID: 32008109
Antibodies to watch in 2019, PMID: 30516432
Antibodies to watch in 2020, PMID: 31847708
For research use only. Not for human or drug use.
